zepbound tirzepatide eli lilly Lilly's weight loss, diabetes drug tops Keytruda as world's best-selling medicine Lilly's KwikPen Delivers Month of

Nine out of ten people responded

Food and Drug Administration approved semaglutide for chronic weight management based on trials pairing the drug with a reduced-calorie diet and increased physical activity

Most patients report noticeable appetite suppression and reduced food cravings within the first one to two weeks of starting Zepbound at the 2.5 mg dose

Same syringe reading, different dose

Where semaglutide jumps from 1.0 mg to 1.7 mg with no option in between, tirzepatide offers 7.5 mg as an intermediate between 5 mg and 10 mg, and 12.5 mg as an intermediate between 10 mg and 15 mg

Tirzepatide has been linked to an increased risk of thyroid cancer, including medullary thyroid carcinoma (thyroid C-cell tumors)